New drug combo may boost stem cell success in rare bone marrow cancer
NCT ID NCT07471503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a type of bone marrow cancer) have better outcomes. About 39 adults aged 18-75 with intermediate- or high-risk myelofibrosis will take part. The goal is to see if the drug reduces serious complications like graft-versus-host disease and relapse, while improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new drug combo reset the immune system to beat relapsed leukemia?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- New study aims to predict hidden hepatitis b danger in transplant patients
- New combo therapy hopes to shrink spleens and ease symptoms in Tough-to-Treat myelofibrosis
- New drug aims to stop anemia after stem cell transplants